UiPath Inc. (NASDAQ:PATH) Shares Purchased by Hamilton Lane Advisors LLC

Hamilton Lane Advisors LLC increased its stake in shares of UiPath Inc. (NASDAQ:PATH) by 9.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 180,566 shares of the healthcare company’s stock after purchasing an additional 15,114 shares during the quarter. UiPath accounts for approximately 1.6% of Hamilton Lane Advisors LLC’s holdings, making the stock its 10th biggest position. Hamilton Lane Advisors LLC’s holdings in UiPath were worth $9,500,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of PATH. Price T Rowe Associates Inc. MD acquired a new stake in shares of UiPath during the second quarter worth $1,521,290,000. ARK Investment Management LLC acquired a new stake in shares of UiPath during the second quarter worth $806,729,000. Coatue Management LLC acquired a new stake in shares of UiPath during the second quarter worth $769,807,000. Sumitomo Mitsui Trust Holdings Inc. acquired a new stake in shares of UiPath during the second quarter worth $409,526,000. Finally, Nikko Asset Management Americas Inc. acquired a new stake in shares of UiPath during the second quarter worth $411,517,000. 31.82% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts have commented on PATH shares. Oppenheimer reissued a “hold” rating on shares of UiPath in a report on Wednesday, September 8th. Royal Bank of Canada reduced their target price on UiPath from $74.00 to $65.00 and set a “sector perform” rating for the company in a report on Thursday, October 7th. Needham & Company LLC reissued a “buy” rating and issued a $85.00 target price on shares of UiPath in a report on Wednesday, October 6th. Credit Suisse Group started coverage on UiPath in a report on Tuesday, November 16th. They issued an “outperform” rating and a $75.00 target price for the company. Finally, Cowen reduced their target price on UiPath from $80.00 to $72.00 and set an “outperform” rating for the company in a report on Friday, October 8th. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $71.00.

In other UiPath news, CRO Thomas Neergaard Hansen sold 80,000 shares of UiPath stock in a transaction dated Thursday, September 9th. The stock was sold at an average price of $56.16, for a total value of $4,492,800.00. Following the completion of the sale, the executive now owns 1,402,723 shares in the company, valued at approximately $78,776,923.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Daniel Dines sold 16,993 shares of UiPath stock in a transaction dated Tuesday, November 16th. The shares were sold at an average price of $56.01, for a total value of $951,777.93. The disclosure for this sale can be found here. Insiders sold a total of 401,357 shares of company stock valued at $22,592,750 in the last 90 days. 28.60% of the stock is owned by company insiders.

UiPath stock traded up $1.29 during midday trading on Thursday, reaching $49.16. 2,655,644 shares of the company were exchanged, compared to its average volume of 4,148,027. The firm’s 50-day simple moving average is $52.58 and its 200-day simple moving average is $61.80. UiPath Inc. has a 1 year low of $46.66 and a 1 year high of $90.00.

UiPath (NASDAQ:PATH) last posted its quarterly earnings data on Monday, September 6th. The healthcare company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.06. The company had revenue of $195.52 million for the quarter, compared to analysts’ expectations of $186.72 million. The company’s revenue was up 40.3% on a year-over-year basis. On average, equities analysts predict that UiPath Inc. will post -0.82 EPS for the current year.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. It develops UiPath Studio, a platform designed for RPA developers looking to build complex process automations with built-in governance capabilities, such as robust debugging tools, application programming interface automation, wizards to automate desktop or web applications, leverage custom code, and to integrate machine learning models into production workflows.

See Also: FTSE 100 Index

Want to see what other hedge funds are holding PATH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UiPath Inc. (NASDAQ:PATH).

Institutional Ownership by Quarter for UiPath (NASDAQ:PATH)

Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.